10-Q: Silexion Therapeutics Faces Nasdaq Delisting Risk Amidst Legal Battle

Silexion Therapeutics Corp's Q3 2026 filing reveals ongoing financial challenges, Nasdaq listing non-compliance, and a significant legal dispute, overshadowing progress in its SIL204 clinical trial.

Summary

• Silexion Therapeutics Corp reported a net loss of $8.8 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period.
• The company is facing non-compliance with Nasdaq's minimum shareholders' equity ($2.5 million) and minimum bid price ($1.00) requirements.
• A significant legal dispute exists with Moringa Sponsor, LP, concerning the conversion of a $3.433 million promissory note.
• Despite financial and listing challenges, the company initiated and dosed the first patient in its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer.
• The company's cash and cash equivalents stood at $4.8 million as of September 30, 2026, with management indicating funds are sufficient for only several months.
• Multiple reverse share splits have been implemented to address the minimum bid price requirement, with a 1-for-24 split effective November 10, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing financial struggles, Nasdaq delisting concerns, and a significant legal dispute with a former sponsor, despite progress in clinical trials.

Positives

• Initiated and dosed the first patient in the Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer.
• Received regulatory approvals for the SIL204 trial in Israel and Germany.
• Reported positive preclinical findings demonstrating SIL204's mechanism of action for cellular internalization and KRAS knockdown.
• Successfully completed several financing transactions in Q3 2026, including an August public offering ($2.5 million) and a September induced warrant exercise ($0.84 million).
• Raised $1.8 million through its At-The-Market (ATM) program in Q3 2026.
• Shareholders approved an increase in authorized share capital in October 2026, providing capacity for future financing.

Negatives

• Reported a net loss of $8.8 million for the nine months ended September 30, 2026, an increase from $7.5 million in the prior year.
• The company has substantial doubt about its ability to continue as a going concern, with current funds sufficient for only several months.
• Received a delisting notice from Nasdaq for non-compliance with minimum shareholders' equity and minimum bid price requirements.
• A significant legal dispute with Moringa Sponsor, LP, seeks repayment of a $3.433 million promissory note, with the company filing a counterclaim.
• Cash and cash equivalents were $4.8 million as of September 30, 2026, insufficient to cover anticipated expenses for the next 12 months.
• Multiple reverse share splits have been implemented, indicating ongoing struggles with share price and Nasdaq compliance.

Risks

• Continued listing on the Nasdaq Capital Market is subject to the discretion of a Nasdaq hearings panel, with potential delisting materially adversely affecting liquidity, market price, and ability to raise capital.
• The company's ability to continue as a going concern is uncertain due to recurring losses and insufficient cash to fund operations for the next 12 months.
• Failure to obtain shareholder approval for future increases in authorized share capital could prevent the company from raising additional equity financing or maintaining its Nasdaq listing.
• The legal proceedings with Moringa Sponsor, LP, could result in significant financial liabilities and distract management.
• The success of the SIL204 clinical trials is uncertain and may not yield favorable results, impacting future development and commercialization.
• The company has never generated revenue from product sales and may never be profitable.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its Phase 2/3 clinical trials for SIL204, seeks marketing approvals, and potentially expands its pipeline. Substantial additional funding will be required, and there is substantial doubt about the company's ability to continue as a going concern.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.
• We expect to continue to incur significant expenses and operating losses for the foreseeable future.
• Our future capital requirements will depend on many factors, including materials costs, regulatory pathway, and human clinical trial costs.
• We believe that the allegations and claims asserted in the complaint [against the company by Moringa Sponsor] are baseless and without merit, and we intend to defend our position vigorously.

Industry Context

StockSavvy.ai notes that Silexion Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on RNAi therapies for KRAS-driven cancers. The company's progress in clinical trials for SIL204 is a positive step, but the significant financial challenges and Nasdaq listing concerns are common hurdles for development-stage biotech firms.

Comparison to Industry Standards

• Biotechnology companies at the clinical-stage often face similar going concern issues, relying heavily on continuous fundraising to advance drug development.
• The need for substantial capital raises, including ATM programs and public offerings, is standard practice for companies like Silexion seeking to fund lengthy and expensive clinical trials.
• Nasdaq listing requirements, particularly minimum bid price and shareholders' equity, are common challenges for smaller biotech firms, often necessitating reverse stock splits or other corrective actions.
• Legal disputes with former sponsors or investors are not uncommon in the SPAC and biotech landscape, reflecting the high-risk, high-reward nature of the industry.

Legal Proceedings

• Moringa Sponsor, LP filed a claim disputing the conversion of a $3.433 million promissory note and seeking cash repayment or alternative repayment, plus damages and legal expenses.
• Silexion Therapeutics has filed a statement of defense and a counterclaim against Moringa Sponsor, LP for $1.169 million plus legal expenses for damages sustained due to the sponsor's actions.

Related Party Transactions

• Share-based compensation expenses included in R&D and G&A were $176k and $298k respectively for the nine months ended Sep 30, 2026.
• Financial expenses (income), net related to related parties was $(307)k for the nine months ended Sep 30, 2026.
• The Related Party Promissory Note of $1,568k outstanding at December 31, 2025, was fully converted into ordinary shares by September 30, 2026.

Stakeholder Impact

• Shareholders face potential dilution from ongoing equity financings and the risk of losing their investment if the company cannot continue as a going concern.
• The Nasdaq delisting risk could significantly reduce the liquidity and market price of ordinary shares and warrants.
• Creditors and suppliers may face uncertainty regarding timely payments given the company's going concern status.
• Employees may face job security concerns due to the company's financial precariousness and potential operational curtailment.

Next Steps

• Continue advancing the Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer.
• Seek marketing approvals for SIL204 in various territories.
• Apply for Orphan Drug Designation in the U.S. and EU for SIL204.
• Continue to monitor and address Nasdaq listing compliance requirements.
• Defend vigorously against the legal claim filed by Moringa Sponsor, LP, and pursue its counterclaim.
• Explore and secure additional financing to fund operations and development activities.

Key Dates

Recommendation

The company is facing significant financial distress, including a going concern warning and Nasdaq delisting threats. The ongoing legal battle with a former sponsor adds substantial risk. While clinical trial progress is noted, the immediate financial and listing challenges outweigh the potential long-term benefits, making it a high-risk investment.

Keywords

biotechnology, oncology, KRAS-driven cancers, RNAi therapeutics, SIL204, pancreatic cancer, clinical trials, Nasdaq listing